← All themes

GLP-1 & Obesity

GLP-1 medicines treat obesity and diabetes, and have grown into one of the largest drug categories ever launched. Their reach extends past medicine, because a change in how much people eat moves whole consumer industries.

92 stocks

Obesity Second-Order Effects

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Eli Lilly LLY $1.12T	3,916	-13	-0.3%	$610B
2	2 Amgen AMGN $235B	2,858	-77	-3%	$121B
3	3 Pfizer PFE $168B	2,816	-123	-4%	$90.5B
4	4 McKesson MCK $116B	1,794	+36	+2%	$80.6B
5	5 Becton Dickinson BDX $52.8B	1,520	-96	-6%	$44.5B
6	6 Novo Nordisk NVO $173B	1,484	-49	-3%	$21.3B
7	7 AstraZeneca AZN $259B	1,224	-29	-2%	$34.7B
8	8 Regeneron Pharmaceuticals REGN $82B	1,203	-90	-7%	$46.9B
9	9 ResMed RMD $34.1B	920	+34	+4%	$23.9B
10	10 Conagra Brands CAG $6.77B	836	-3	-0.4%	$9.02B
11	11 West Pharmaceutical WST $27B	730	+15	+2%	$15.3B
12	12 Lamb Weston LW $7.47B	621	-13	-2%	$6.7B
13	13 DaVita DVA $12.1B	593	-5	-0.8%	$10B
14	14 Teva Pharmaceutical Industries Limited TEVA $47.9B	542	-21	-4%	$11.9B
15	15 Hims & Hers Health HIMS $6.85B	511	+80	+19%	$8.75B
16	16 BellRing Brands BRBR $1.05B	485	-21	-4%	$7.34B
17	17 Viking Therapeutics VKTX $3.48B	392	+19	+5%	$2.02B
18	18 DELISTED WK Kellogg Co KLG	379	-16	-4%	$1.18B
19	19 Embecta EMBC $365M	360	-7	-2%	$557M
20	20 Inspire Medical Systems INSP $2.03B	356	-7	-2%	$4.39B
21	21 Madrigal Pharmaceuticals MDGL $10.6B	305	-16	-5%	$7.13B
22	22 DELISTED Akero Therapeutics AKRO	257	+17	+7%	$4.92B
23	23 Biohaven BHVN $1.73B	249	-17	-6%	$1.23B
24	24 Amphastar Pharmaceuticals AMPH $1.12B	245	+4	+2%	$752M
25	25 Dr. Reddy's Laboratories RDY $10.7B	243	-3	-1%	$1.62B